…emato-oncology service between May 2019 - December 2022.Results ICANS occurred in 48% patients treated(100/208), clinical seizure act…
ICANS
This disease is selected. Its supporting articles are shown below.
Articles mentioning ICANS
7 articles · page 1 of 1…= 53, 76%), acute lymphoblastic leukaemia (ALL, n = 6, 9%), and multiple myeloma (MM, n = 6, 9%). CAR-T products: axicabtagene ciloleucel (n = 3…
…cell (CAR-T) therapy has transformed the treatment landscape of haematological malignancies and is being trialled for autoimmune neurological disorders. Ho…
…the anti-tumor efficacy and all reported toxicities – including ICANS - associated with CAR19 clinical therapy. In our model, intrave…
…ort. 30 CAYA were treated at the RP2D; 28 with B-ALL and 2 with Burkitt lymphoma. Across patients with B-ALL, 20 (71.4%) patients developed cyto…
…myeloma cells, used in relapsed or refractory multiple myeloma (RRMM). While pivotal trials have shown promising results, real-world…
…ptor T-cell (CAR-T) therapy has revolutionised the treatment of haematological malignancies. Despite its efficacy, CAR-T therapy is associated with a high …